BASEL,
Switzerland, Feb. 9
/PRNewswire/ - Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES)
is pleased to announce the signing of its second License Agreement
with Bato Investments, a company based out of Tel-Aviv, Israel.
This Agreement provides for a minimum yearly
order of 500,000 units over a period of 10 years. Both parties have
agreed on an initial price of US$
55.00 per unit, based on the price of the recently
negotiated agreement with Credo-TM, a Company based out of
Russia. Each agreement is
estimated to bring in a gross profit of US$
26,750,000 annually, for a period of ten years. Negotiations
are still ongoing with India,
Pakistan, Spain and Egypt. The terms of these agreements are
projected to be within the same range as the previous ones.
With the signing of this Agreement and ongoing
negotiations, Neuro-Biotech strengthens the implementation of its
Licensees network throughout the world, allowing the Company to
begin the next phase of its development plan: the creation of its
own "Technological Showcase" in order to support the training of
technicians as well as the development of new products and avoid
any type of road show.
For more information on Neuro-Biotech Corp or to
contact a company representative, please visit:
www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made
pursuant to the Safe Harbor Provisions of the Private Securities
Litigation Act of 1995. Certain statements in this press release
may contain words such as "anticipates," "believes," "could,"
"expects," "intends," "may," "projects," "targets" and other
similar language that is considered forward-looking statements.
These forward-looking statements are subject to certain risks and
uncertainties and persons reading this release are cautioned that
such statements are only predictions, and that the Company's actual
future results or performance may be materially different. The
Company disclaims any intention or obligation to update or revise
forward-looking information, whether as a result of new
information, future events, or otherwise, could cause the company's
actual results to differ materially from those indicated in any
forward-looking statements.
SOURCE Neuro-Biotech Corp.
Copyright b. 9 PR Newswire